Amylyx Pharmaceuticals Inc (NAS:AMLX)
$ 2.23 0.01 (0.45%) Market Cap: 151.82 Mil Enterprise Value: -154.85 Mil PE Ratio: 0 PB Ratio: 0.58 GF Score: 21/100

Amylyx Pharmaceuticals Inc at Stifel CNS Days (Virtual) Transcript

Mar 28, 2023 / 03:00PM GMT
Release Date Price: $30.51 (+0.23%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Thanks very much, everybody. It's my pleasure to be hosting the Amylyx team. We've got Josh; Justin; and Jim here. They're going to give kind of a brief update on Amylyx for about 15 minutes, and then we'll have 10 minutes at the end for Q&A. So like with prior analysts, feel free to type a question into the link or shoot me an e-mail, and I certainly have a whole list of my own.

So guys take it away, and thank you again for joining.

Justin B. Klee
Amylyx Pharmaceuticals, Inc. - Co-Founder, Co-CEO & Director

Well, thank you so much, Paul. Thanks, everyone, for joining. So as Paul said, we'll give a brief overview of Amylyx, who we are, and the latest and greatest, and then, yes, I'm very happy to take questions.

So first, just to start, I think we're a really mission-focused company. We're focused in neurodegenerative disease but particularly ALS. So as you'll see through our presentation

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot